Premium
Efalizumab for severe palmo‐plantar psoriasis: an open‐label pilot trial in five patients
Author(s) -
Brunasso AMG,
Salvini C,
Massone C
Publication year - 2009
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2008.03062.x
Subject(s) - efalizumab , medicine , psoriasis , plaque psoriasis , quality of life (healthcare) , dermatology , open label , clinical trial , nursing
Background Palmo‐plantar psoriasis (PPP) is a disabling condition that significantly impairs quality of life. PPP tends to be resistant to conventional therapies and may last for several years. Topical treatments are usually ineffective. Systemic therapy with oral retinoids and psoralen plus ultraviolet A is frequently required, although it rarely leads to remission. Study design We conducted an open‐label, pilot study to evaluate treatment of PPP with efalizumab, an anti‐CD11a monoclonal antibody approved for the treatment of chronic, refractory moderate to severe plaque psoriasis in adults. Methods Five patients with severe PPP received efalizumab treatment for 24 weeks. Results All five patients responded favourably by week 12 and showed further improvement at week 24 of uninterrupted therapy. Mean physician‐assessed severity scores and patient‐reported outcome scores improved almost 75% after 12 weeks and 90% after 24 weeks. At week 32, three patients maintained the response seen at week 24, while two patients suspended efalizumab. Conclusions Efalizumab therapy was well tolerated and effective in five patients with severe PPP, allowing a significant improvement in quality of life. Conflicts of interest None declared